Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omega-3 fatty acids + morphine
- Development stage
- Unknown
- Lead developer
- National University of La Rioja
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy involves the use of **omega-3 fatty acids** (typically containing eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) as an adjunct to the opioid analgesic **morphine**. The rationale behind this combination is to leverage the anti-inflammatory and potentially neuroprotective properties of omega-3 fatty acids to enhance the analgesic efficacy of morphine and reduce the total opioid requirement (opioid-sparing effect) in the management of acute postoperative pain. Omega-3 fatty acids are thought to modulate pain signaling by reducing the production of pro-inflammatory eicosanoids and cytokines. This specific regimen is being investigated by the National University of La Rioja for patients undergoing laparoscopic cholecystectomy.
- Other names
- omega-3 fatty acids and morphineomega3 fatty acids and morphineomega 3 fatty acids and morphine
02
Targets
PPARD (Peroxisome proliferator–activated receptor delta)MOR (Mu opioid receptor)PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)COXLPL (Lipoprotein lipase)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on omega-3 fatty acids + morphine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omega-3 fatty acids + morphine.